The Fort Worth Press - Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth

USD -
AED 3.672504
AFN 64.000368
ALL 80.660025
AMD 364.155001
ANG 1.790365
AOA 918.000367
ARS 1524.750402
AUD 1.417435
AWG 1.8
AZN 1.70397
BAM 1.716593
BBD 2.014833
BDT 123.096502
BGN 1.683441
BHD 0.377145
BIF 3013.033747
BMD 1
BND 1.278097
BOB 12.259622
BRL 5.188104
BSD 1.000307
BTN 95.794093
BWP 13.621802
BYN 3.022425
BYR 19600
BZD 2.011937
CAD 1.41495
CDF 2340.000362
CHF 0.828271
CLF 0.024357
CLP 961.770396
CNY 6.71325
CNH 6.734304
COP 3348.488173
CRC 454.820731
CUC 1
CUP 24.008426
CVE 96.778865
CZK 21.384404
DJF 178.136657
DKK 6.562804
DOP 59.49006
DZD 133.78604
EGP 51.914688
ERN 15
ETB 162.282003
EUR 0.87791
FJD 2.24725
FKP 0.754991
GBP 0.754689
GEL 2.61504
GGP 0.754991
GHS 11.618906
GIP 0.754991
GMD 73.503851
GNF 8797.998859
GTQ 7.639444
GYD 209.30355
HKD 7.84345
HNL 26.849519
HRK 6.613804
HTG 130.916751
HUF 320.61504
IDR 17914.1
ILS 3.04806
IMP 0.754991
INR 95.817504
IQD 1310.484048
IRR 1374575.000352
ISK 120.260386
JEP 0.754991
JMD 158.265678
JOD 0.70904
JPY 157.28504
KES 129.644095
KGS 87.448204
KHR 4068.10901
KMF 433.00035
KPW 900.000318
KRW 1355.185039
KWD 0.30864
KYD 0.833633
KZT 443.156186
LAK 22438.232325
LBP 89581.428007
LKR 330.293588
LRD 172.063018
LSL 16.32106
LTL 2.95274
LVL 0.60489
LYD 6.395752
MAD 9.599596
MDL 17.756616
MGA 4416.553298
MKD 54.043972
MMK 2099.795344
MNT 3598.18988
MOP 8.082152
MRU 40.243999
MUR 47.530378
MVR 15.450378
MWK 1734.585509
MXN 17.679204
MYR 4.074104
MZN 63.910377
NAD 16.32106
NGN 1326.380377
NIO 36.810462
NOK 9.50785
NPR 153.270725
NZD 1.749629
OMR 0.385571
PAB 1.000307
PEN 3.395971
PGK 4.456927
PHP 62.347038
PKR 277.197262
PLN 3.83775
PYG 5896.344407
QAR 3.646377
RON 4.629204
RSD 103.085092
RUB 84.346338
RWF 1478.474569
SAR 3.752852
SBD 8.000512
SCR 13.902664
SDG 601.503676
SEK 9.91775
SGD 1.277904
SHP 0.755002
SLE 24.650371
SLL 20969.491881
SOS 571.729495
SRD 37.667504
STD 20697.981008
STN 21.503489
SVC 8.753236
SYP 13002.000254
SZL 16.317198
THB 33.375038
TJS 9.228244
TMT 3.51
TND 2.961425
TOP 2.40776
TRY 48.942504
TTD 6.803879
TWD 31.728704
TZS 2654.934831
UAH 44.794751
UGX 3918.023434
UYU 40.075482
UZS 11839.206565
VES 852.43145
VND 25976
VUV 118.485868
WST 2.745655
XAF 575.871484
XAG 0.015553
XAU 0.000233347179
XCD 2.70255
XCG 1.80287
XDR 0.707052
XOF 575.871484
XPF 104.673717
YER 236.650363
ZAR 16.304245
ZMK 9001.203584
ZMW 19.513758
ZWL 321.999592
SSP 5712.5919
MXV 2.00344
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth

Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth

New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision.

Text size:

FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth.

Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and managed services portfolios are all launching new offerings in the second half of 2026, and Tubbs' track record of delivering strong client experiences will be key as those launches roll out.

"Ryan has built and led high-performing commercial and customer organizations at scale," said Tom Langan, CEO, Envision Pharma Group. "As we bring sales enablement, lead generation, marketing, and customer success together under one leader, reporting to Jay Ferro, President, Technology and Chief Product Officer, Ryan is exactly the right person to build the connective tissue our clients and our business need, giving every business unit the infrastructure to grow and making it simpler for clients to access the full breadth of Envision."

Tubbs brings more than two decades of commercial and customer leadership experience across enterprise software, healthcare and life sciences, higher education, and public sector organizations. He most recently served as SVP, Customer Success, Value & Managed Services at Ellucian, leading a global post-sale organization, driving retention, expansion, and margin performance. Earlier, he spent 13 years at Microsoft in senior commercial and transformation roles, where he modernized commercial operations for a $2 billion enterprise services business. Tubbs co-founded BillionMinds, a Techstars-backed workforce development company, and holds an MBA from Duke University's Fuqua School of Business and a BS in Chemical Engineering from North Carolina State University.

"Envision has extraordinary expertise, technology, and client relationships," said Tubbs. "The opportunity now is to connect those strengths into one commercial engine, making it easier for our teams to bring the best of Envision to every client and easier for clients to access the full value we can deliver."

###

About Envision Pharma Group

Envision Pharma Group is a global, technology-enabled solutions partner to the life sciences industry. We unleash the power of combined intelligence - human expertise and technology - to advance how scientific innovation translates into improved patient outcomes. We unite scientific expertise, strategic insight, and AI-powered technology to help clients create, communicate, and demonstrate value, accelerating access to life-changing treatments. With more than 20 years of experience and trusted partnerships with 400+ biopharma companies, including all top 20 pharma, we deliver integrated solutions across the product life cycle, from medical communications to commercialization and compliance, through flexible models that scale to client needs. Together, we combine human insight and technology to drive smarter decisions, measurable impact, and sustainable growth.

Learn more: www.envisionpharmagroup.com

For more information, contact:

Sophie Berger, Global Head, Marketing, Envision Pharma Group
Email: [email protected]

Brittany Bowen, Media Relations, Geben Communication
Email: [email protected]

SOURCE: Envision Pharma Group



View the original press release on ACCESS Newswire

P.McDonald--TFWP